n=318 | |
---|---|
Age (years), n (%) | |
<60 | 93 (29) |
60 – 70 | 137 (43) |
>70 | 88 (28) |
Sex (M/F), n (%) | 196/122 (62/38) |
ECOG PS, n (%) | |
0 | 204 (64) |
1 | 96 (30) |
2 or more | 17 (5) |
Body mass index (kg/m2), n (%) | |
<22 | 198 (62) |
≥22 | 120 (38) |
Tumor resection, n (%) | 44 (14) |
Pancreatic tumor location, n (%) | |
Head | 165 (52) |
Body | 94 (30) |
Tail | 59 (19) |
Tumor size (mm), n (%) | 32 (1 – 98) |
<20 | 41 (13) |
20 – 40 | 181 (57) |
>40 | 96 (30) |
Histology, n (%) | |
Adenocarcinoma | 271 (85) |
Others | 47 (15) |
Unknown | 37 (12) |
Site of metastatic disease, n (%) | |
Liver | 154 (48) |
Peritoneum | 62 (19) |
Lung | 39 (12) |
Number of metastatic sites, n (%) | |
≥2 | 97 (31) |
Ascites, n (%) | 62 (19) |
Albumin (g/dL), n (%) | |
>4 | 32 (10) |
3 – 4 | 181 (57) |
<3 | 105 (33) |
LDH (U/L), n (%) | |
<240 | 269 (85) |
240 – 360 | 105 (33) |
>360 | 8 (3) |
CRP (mg/dL), n (%) | |
<0.3 | 158 (50) |
0.3 – 3.0 | 117 (37) |
>3.0 | 43 (14) |
CA19–9 (U/mL), n (%) | |
<37 | 76 (24) |
37 – 370 | 72 (23) |
>370 | 170 (53) |
AJCC TNM stage, n (%) | |
III | 63 (20) |
IV | 255 (80) |
First line regimen, n (%) | |
GnP | 200 (63) |
FFX | 118 (37) |